KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Ifinatamab deruxtecan (Primary) ; Raludotatug deruxtecan (Primary) ; Docetaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms KEYMAKER-U01 Substudy 01H
- Sponsors Merck Sharp & Dohme
- 23 Jan 2025 New trial record